Sanofi

Pieris Pharmaceuticals Gmbh

Michael Mourez

Christine Rothe

Andrea Allersdorfer

Marlon Hinner

Alexander Wiedenmann

Jochen Kruip

Kristian Hobolt Jensen

Carsten Corvey

Bradley Lunde

Laurent Fraisse

Martin Hülsmeyer

Heike Stump

Astrid Rey

Bernhard Calandra

Nathalie Karst

Christian Lange

Ingo Focken

Hans-Falk Rasser

Dorothea Rat

Thomas Stuedemann

Juergen Schaefer

Bernard Calandra

The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth ofand/or to prevent or treatbiofilm infection as well as diseases or disorders associated withbiofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.

Fusion molecules

The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.

Proteins specific for pyoverdine and pyochelin

Growing community of inventors

Toulouse, France

Michael Mourez